双效支气管扩张剂AZD8871用于慢性阻塞性肺疾病的随机试验 - Suppr | 超能文献

相似文献

1

A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease.双效支气管扩张剂AZD8871用于慢性阻塞性肺疾病的随机试验

Am J Respir Crit Care Med. 2019 May 15;199(10):1282-1284. doi: 10.1164/rccm.201812-2345LE.

2

Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease.支气管扩张剂联合疗法治疗慢性阻塞性肺疾病

Curr Clin Pharmacol. 2011 Feb;6(1):48-61. doi: 10.2174/157488411794941331.

3

▼Olodaterol--another LABA for COPD.▼奥达特罗——慢性阻塞性肺疾病的另一种长效β2受体激动剂。

Drug Ther Bull. 2015 Apr;53(4):42-5. doi: 10.1136/dtb.2015.4.0319.

4

[New bronchodilators and combinations in COPD treatment].[慢性阻塞性肺疾病治疗中的新型支气管扩张剂及联合用药]

Tuberk Toraks. 2016 Sep;64(3):240-245.

5

Role of Long-Acting Muscarinic Antagonist/Long-Acting β-Agonist Therapy in Chronic Obstructive Pulmonary Disease.长效毒蕈碱拮抗剂/长效β受体激动剂疗法在慢性阻塞性肺疾病中的作用

Ann Pharmacother. 2017 Aug;51(8):696-705. doi: 10.1177/1060028017705149. Epub 2017 Apr 14.

6

Long-Acting β-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1641-1644. doi: 10.1164/rccm.201710-2052LE.

7

Tiotropium versus salmeterol in COPD.噻托溴铵与沙美特罗治疗慢性阻塞性肺疾病的比较

N Engl J Med. 2011 Jun 30;364(26):2553; author reply 2553-4. doi: 10.1056/NEJMc1104617.

8

Inhaled corticosteroids in COPD: the final verdict is….慢性阻塞性肺疾病中的吸入性糖皮质激素：最终结论是……

Eur Respir J. 2018 Dec 13;52(6). doi: 10.1183/13993003.01940-2018. Print 2018 Dec.

9

Future of chronic obstructive pulmonary disease management.慢性阻塞性肺疾病管理的未来。

Expert Rev Respir Med. 2012 Jun;6(3):285-99. doi: 10.1586/ers.12.20.

10

Multivalent dual pharmacology muscarinic antagonist and β₂ agonist (MABA) molecules for the treatment of COPD.用于治疗慢性阻塞性肺疾病（COPD）的多价双重药理学毒蕈碱拮抗剂和β₂激动剂（MABA）分子

Prog Med Chem. 2012;51:71-95. doi: 10.1016/B978-0-12-396493-9.00003-0.

引用本文的文献

1

The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and β Adrenergic Receptor Agonist Navafenterol in Human Small Airways.双重药理学（毒蕈碱受体拮抗剂和β肾上腺素能受体激动剂纳伐特罗）对人小气道的支气管保护作用。

Cells. 2023 Jan 6;12(2):240. doi: 10.3390/cells12020240.

2

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease.正在研究用于治疗慢性阻塞性肺疾病的长效毒蕈碱拮抗剂。

J Exp Pharmacol. 2020 Dec 8;12:559-574. doi: 10.2147/JEP.S259330. eCollection 2020.

3

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies.